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Intermittent preventive treatment of malaria in pregnancy is a highly cost-effective intervention which significantly
improves maternal and birth outcomes among mothers and their newborns who live in areas of moderate to high
malaria transmission. However, coverage in sub-Saharan Africa remains unacceptably low, calling for urgent action
to increase uptake dramatically and maximize its public health impact. The ‘Global Call to Action’ outlines priority
actions that will pave the way to success in achieving national and international coverage targets. Immediate action is
needed from national health institutions in malaria-endemic countries, the donor community, the research community,
members of the pharmaceutical industry and private sector, along with technical partners at the global and local levels,
to protect pregnant women and their babies from the preventable, adverse effects of malaria in pregnancy.
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Historic progress in malaria control has resulted in decreased
malaria-attributable mortality worldwide by 47 % since
2000 [1]. However, progress in the prevention of malaria
in pregnancy (MiP) during the same time period has
been less remarkable. Close to 32 million pregnancies
occur every year in areas of stable malaria transmission
where the World Health Organization (WHO) recom-
mends a three-pronged approach to control MiP: the
provision of intermittent preventive treatment in preg-
nancy (IPTp) using sulphadoxine-pyrimethamine (SP),
the use of insecticide-treated nets (ITNs), and effective
case management of malaria illness and anaemia [2, 3].
IPTp is a highly cost-effective intervention with the po-
tential to reduce maternal morbidity and neonatal mor-
tality [4]. Meta-analyses of women in their first and
second pregnancies have shown that IPTp decreases the* Correspondence: Jenny.Hill@lstmed.ac.uk
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maternal anaemia by 40 %, and neonatal mortality by
38 %, although the evidence on neonatal mortality is less
conclusive [5]. IPTp with SP remains effective in pre-
venting the adverse consequences of malaria in preg-
nancy across a wide range of SP resistance levels [6].
The use of IPTp with SP, together with ITNs, remains
essential for protecting pregnant women against malaria
infection and the adverse birth outcomes associated with
MiP in sub-Saharan Africa [7].
Despite being a straightforward intervention that can
be delivered to pregnant women under direct observa-
tion during routine antenatal care (ANC) visits, IPTp
coverage remains unacceptably low. In 2013, average
coverage of at least two doses of IPTp among pregnant
women in sub-Saharan African countries was 24 %, well
below national and international targets, and only mar-
ginally higher than a decade earlier when coverage was
14 % [8]. Just six countries in sub-Saharan Africa have
reached the 2005 coverage target of 60 % set by the Roll
Back Malaria Partnership (RBM); not one country has
reached the 2010 RBM target of 80 % coverage [9, 10].icle distributed under the terms of the Creative Commons Attribution License
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million of the 35 million pregnant women in sub-
Saharan Africa malaria-endemic countries did not re-
ceive a single dose of IPTp in 2013 [1].
In 2012, WHO updated its IPTp policy to recommend
that SP be administered as early as possible during the
second trimester and at every scheduled ANC visit
thereafter, so long as the doses are given at least one
month apart [11]. This update was, in part, aimed at in-
creasing the number of SP doses administered; IPTp has
the lowest coverage among all interventions delivered to
pregnant women through the ANC platform, including
the provision of long-lasting insecticide-treated nets
[12]. The discrepancy between high ANC attendance
(75 % of women in sub-Saharan Africa attend at least
twice) and low IPTp coverage points to substantial
missed opportunities at ANC facilities [8, 13].
What can be done to close this gap?
In 2013, the RBM MiP Working Group released a
Consensus Statement, calling on stakeholders to renew
their commitment to scale-up malaria control interven-
tions that target pregnant women and to take action that
would: (1) harmonize national reproductive health and
malaria policies in support of WHO’s three-pronged strat-
egy against MiP; (2) strengthen health systems; and (3) im-
prove monitoring and evaluation of MiP programme
effectiveness. The recent RBM report on the contribution
of malaria control to maternal and newborn health
highlighted key programme areas for improvement that
will contribute to the scale-up of MiP interventions [14].
The report states that many barriers to IPTp uptake are
common across countries and can be overcome relatively
easily and rapidly [14]. These obstacles include a lack of in-
tegration and coordination between national reproductive
health and malaria control programmes. Better coordin-
ation is central to preventing MiP given that interventions
are delivered through ANC clinics with management from
staff in reproductive health services and technical oversight
from counterparts in malaria control. Other obstacles in-
clude: inconsistent, unclear and poorly disseminated infor-
mation on IPTp policy; confusion among healthcare
providers as to when and how to administer IPTp; SP
stock-outs at ANC clinics [15], and well-documented bar-
riers to accessing ANC services [16]. Additional obstacles
relate to broader health systems issues and necessitate
strengthening the health system generally and ANC ser-
vices specifically.
In order to reinforce stakeholder commitment to in-
creasing IPTp coverage, a ‘Global Call to Action for the
scale-up of IPTp’ was held during the 63rd Annual
Meeting of the American Society of Tropical Medicine
and Hygiene [17]. Based on previous reports, a set of
recommendations was developed and further elaboratedthrough a series of consultations among key stake-
holders [14, 18]. The recommendations address key
challenges to the scale-up of IPTp that are required to
maximize its public health impact. The ongoing revision
of the WHO ANC guidelines represents a strategically
crucial opportunity for MiP to be re-prioritized as a core
component of focused ANC.
Recommendations by key stakeholders
National level
Commitment from malaria-endemic countries to scale-up
IPTp is pivotal to creating momentum that is sustained—if
not accelerated—towards reaching coverage targets. Im-
mediate actions as listed in Table 1 can be pursued with-
out delay and, indeed, are critical to curbing the adverse
consequences of MiP.
On the supply side, endorsement of IPTp and deliber-
ate integration of ANC services is needed across public
health programmes including reproductive health, mal-
aria, HIV and TB. This will require that healthcare pro-
viders are trained on, and have access to, the updated
WHO guidelines on IPTp administration. A recent re-
view of national MiP policies, guidelines, and training
tools in five countries found that many documents were
outdated and/or discordant between national malaria
programmes and reproductive health programmes,
which could lead to incorrect practices (such as with-
holding IPTp due to misunderstanding the appropriate
gestational age for administering IPTp) among ANC
healthcare providers [19]. Low-cost visual job aids for
healthcare providers that communicate clear messages
on the timing, spacing and dosage of IPTp as described
elsewhere [20] should be widely used. Previous experi-
ence has shown that community-based promotion or
distribution of IPTp, alongside promotion of ANC ser-
vices, is effective at increasing coverage in some settings
[21–24]. Earmarked funding that ensures a steady supply
of quality SP and low-dose folic acid (0.4 mg) is recom-
mended for use in conjunction with IPTp-SP (a daily
dose of folic acid that is equal or greater than 5 mg has
been shown to counteract the anti-malarial effect of SP
[25, 26]), and that these are to be provided free-of-
charge to pregnant women at ANC clinics. Simply mak-
ing sure that drinking water and cups are available for
women to use is key to preventing countless missed
opportunities.
On the demand side, broad community engagement,
targeted promotional campaigns and empowering
women with information on the benefits of IPTp and
other services provided at ANC facilities are also import-
ant. A systematic review identified several barriers to
IPTp uptake including a lack of community knowledge
about the advantages of IPTp, the safety of SP use in
pregnancy, the recommended dosing schedule for IPTp,
Table 1 Recommended actions for the scale-up of IPTp
Health system
building blocks
Key health-system programme
areas for the scale-up of IPTp [15]
Who What
Governance Integration between programmes
at the ANC platform
➢ National health institutions
in malaria-endemic countries
➢ Establish or strengthen national technical
working groups on, or including, MiP to
improve the quality of service delivery of
focused ANC in both the public and
private sectora
Policy ensuring consistent, clear
and widely disseminated information
➢ National health institutions
in malaria-endemic countries
➢ Disseminate clear guidelines with simplified
language for IPTp based on the WHO 2012
policy update and ensure that IPTp is in
national strategic and operational plans
Financing Finance for health systems strengthening
with focus on the ANC platform and removing
costs as a barrier to ANC and IPTp uptake as
well as support operational research
➢ National health institutions
in malaria-endemic countries
➢ Reduce, or eliminate where possible, ANC
fees to overcome cost as a barrier to ANC
access for end-users and the uptake of IPTp
➢ Donor community ➢ Increase levels of financial support for
health systems strengthening with focus
on the ANC platform
➢ Provide support for operational research
to improve the quality of service delivery
and increase IPTp coverage
➢ Promote the inclusion of IPTp and
malaria control in pregnancy within
grant proposals (e.g. The Global Fund
and President’s Malaria Initiative) from
endemic countries, alongside all programme
areas of health systems strengthening
➢ Support private sector engagement
in increasing funding and support for
improved IPTp coverage
Human Resource Capacity development to improve
healthcare provider knowledge and
skills for the delivery of IPTp
➢ National health institutions
in malaria-endemic countries
➢ Ensure healthcare providers in the public
and private sectors have access to and
training on the updated IPTp guidelines
Product &
Technology
Commodities supply chain
management strengthening
➢ National health institutions
in malaria-endemic countries
➢ Earmark funding for procurement for
IPTp delivery through ANC channels in
both the public and private sector
to prevent stock-outs
➢ Pharmaceutical industry ➢ Meet the demand for SP procurement
and register quality SP in all
malaria-endemic countries
➢ Meet the demand for procurement
and register low-dose folic acid in all
malaria-endemic countries
➢ Identify and develop new drugs
suitable for use as IPTp
Health Management
Information Systems
Monitoring and evaluation to assess
IPTp effectiveness and progress and
challenges to delivery and uptake
at national and local levels
➢ National health institutions
in malaria-endemic countries
➢ Ensure IPTp coverage indicators are in
line with new policy
➢ Use District Health Management
Information System (HMIS) to measure
coverage of IPTp, report changes in
coverage, identify bottlenecks and
take necessary action
➢ Research community;
National health institutions
in malaria-endemic
countries and WHO
➢ Collaborate with WHO and Ministries
of Health to establish monitoring
and evaluation plans for:
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Table 1 Recommended actions for the scale-up of IPTp (Continued)
◦ SP resistance and its impact
on IPTp-SP effectiveness;
◦ Reducing malaria transmission and
its impact on IPTp-SP effectiveness;
◦ Data on uptake and coverage of
IPTp from district and facility levels
that will help to identify
implementation bottlenecks.
Service Delivery Quality assurance to monitor
implementation and eliminate
gaps in service delivery
➢ National health institutions
in malaria-endemic countries
➢ Explore innovative opportunities in the
community for service delivery, both
to extend antenatal clinic-based
programmes and to serve women where
ANC services are under-developed
➢ Research community ➢ Evaluate alternative strategies for the
delivery of IPTp in hard-to-reach
populations or communities
Community engagement to promote
ANC, raise awareness of IPTp benefits
and increased uptake of IPTp
➢ National health institutions
in malaria-endemic countries
➢ Undertake targeted communication
campaigns at both the community and
facility levels to promote ANC attendance
among pregnant women and to raise
awareness of the benefits of IPTp
➢ Research community ➢ Identify, promote and evaluate
successful behaviour change
communication strategies based
on the RBM toolkitb to:
◦ Increase demand and acceptance
of IPTp-SP by pregnant women;
◦ Improve healthcare provider
attitudes and performance;
Abbreviations: ANC antenatal care, IPTp intermittent preventive treatment for malaria in pregnancy, RBM Roll Back Malaria Partnership, SP sulphadoxine-pyrimethamine,
WHO World Health Organization
aNon-governmental sector in this context includes private practitioners, faith-based organizations and other non-governmental organizations that provide health
services outside of the Ministry of Health
bhttp://www.rollbackmalaria.org/files/files/partnership/wg/wg_communication/docs/Malaria-BCC-Indicators-Reference-Guide.pdf
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Addressing the main barriers to ANC attendance such
as out-of-pocket costs, negative staff attitudes often
expressed verbally and non-verbally towards patients,
and long waiting times could contribute to better uptake
of IPTp as well as other ANC services across socio-
economic groups and reduce inequities to access [16].
The non-governmental sector—comprised of private
practitioners, faith-based organizations and other non-
governmental organizations—provides up to 60 % of
health services in some countries [27]. Consequently,
this sector is critical to the scale-up of IPTp and must
be incorporated into efforts aimed at health system
strengthening including health worker training, support-
ive supervision, and preventing SP stock outs. Continu-
ous monitoring and evaluation through the use of health
management information systems will enable countries
to track their own progress and identify bottlenecks in
the delivery of IPTp. This will require updating informa-
tion systems and ANC registers to collect data on IPTp
doses given at every ANC visit, in line with the updated
WHO policy recommendation. Civil society can alsoplay an important role by reinforcing the importance of
IPTp to communities at risk of malaria and holding gov-
ernments accountable for the delivery of IPTp.
International level
At the international level, the RBM MiP Working Group
provides strategic advice and technical guidance on best
practices for the scale-up of MiP interventions, including
IPTp. Donors and multilateral organizations such as the
Global Fund, the World Bank, the Bill and Melinda
Gates Foundation, UNICEF and international aid agencies
[e.g. the President’s Malaria Initiative (US Agency for
International Development and US Centers for Disease
Control and Prevention) and the UK Department for
International Development], should work in close partner-
ship with the RBM MiP working group to advocate for
and to support health systems strengthening and oper-
ational research that is focused on IPTp, both of which are
required to meet targets and sustain results.
The pharmaceutical industry has a fundamental role in
producing good-quality, safe, well-tolerated, efficacious,
and affordable medicines that are accessible to
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pharmaceutical industry should consider working with
the 36 malaria-endemic countries that have an IPTp pol-
icy to facilitate the availability of SP and low-dose folic
acid [25, 26]. Procurement of SP has been a challenge due
to its transition from the first-line treatment for uncompli-
cated malaria to comparatively limited use in IPTp, and
more recently, seasonal chemoprophylaxis in children
when combined with amodiaquine. Together with the re-
search community, the pharmaceutical industry is encour-
aged to play an important role in identifying alternative
drugs that can be used for IPTp in areas where SP may be
a sub-optimal therapy due to increasing parasite resistance.
The research community needs to facilitate implementa-
tion of evidence-based practices, while continuing to play a
key role in supporting the scale-up of IPTp. Operational re-
search is needed to evaluate strategies—both existing and
new—that are designed to increase antenatal care-seeking
behaviour, especially early in pregnancy, and to improve
healthcare provider attitudes exhibited towards pregnant
women who present at ANC facilities. Further operational
research is needed to evaluate community distribution of
IPTp that seeks to increase IPTp uptake while not discour-
aging ANC attendance. Continued collaboration with
WHO and Ministries of Health will be required to monitor
IPTp effectiveness and to foster data-driven decision-
making by programme managers to identify bottlenecks in
IPTp provision and prioritize appropriate action.
Prevention of MiP is a core component of maternal and
newborn health. IPTp is a highly cost-effective tool that
has been proven to prevent maternal and neonatal deaths
and should be made a top priority. International coverage
targets can be reached through a combination of powerful
advocacy, firm political and financial commitments, and
strong local, national and international partnerships. An
immediate need is for countries to develop consensus
around country- and district-level action plans for the
scale-up of IPTp that have been adapted to local require-
ments with support from technical partners.
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